ClinicalTrials.gg
Active, not recruitingNCT05270837PEGASUSUpdated Jul 21, 2026Results posted

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

A Phase 3 interventional study of Pegvaliase and Diet Only in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Active, not recruiting at 16 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
4th of 10
55 · median 39
Started
2022
the only one that year
Phase 3
4 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 4 in phase 3, and was the 9th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.

Read the detailed description

This Phase 3 multicenter study is designed to evaluate the safety and efficacy of pegvaliase administered daily to adolescents (ages 12 to 17 years old (US), inclusive, and 12 to 15 years old (EU), inclusive 12-17) with phenylketonuria (PKU). Participants will be randomized in a 2:1 ratio to the active (pegvaliase) and control (diet-only) treatment arms, respectively, with 36 participants receiving pegvaliase and 18 participants managing their PKU with diet alone.

03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • PKU
  • BioMarin
  • Phenylketonuria
  • BMN165
  • PAL
  • Subcutaneous Injections
  • Pegvaliase
  • adolescent PKU
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 12 to 17 years old (US), inclusive, or 12 to 15 years (EU), inclusive, at the start of the Screening/Run-in Period (Day -28).
  • Diagnosis of PKU and failure to maintain recommended blood Phe levels on existing management (sapropterin dihydrochloride and Phe-restricted diet) demonstrated by 2 blood Phe concentration measurements > 600 μmol/L during the Screening/Run-in Period (7 to 10 days in between blood Phe assessments) and average blood Phe concentration > 600 μmol/L over the past 12 months (per available data).
  • Willing and able to maintain and adjust dietary and medical protein food intake according to the study protocol under the supervision of a study dietician or adequately trained designee per investigator discretion during study participation.
  • If on medication for ADHD, depression, or other psychiatric disorder, stable dose of medication for ≥ 8 weeks prior to enrollment and willing to maintain stable dose unless a change is medically indicated.
  • An adult (≥ 18 years of age) has been identified who is willing and competent to observe the participant during study drug administration and for a minimum of 1 hour following administration.
  • Participants must be capable of giving signed
  • If sexually active, male or female participants must not plan to become pregnant (self or partner) and must use 2 acceptable methods of while participating in the study beginning at Screening and for 4 weeks after discontinuing study drug.

Exclusion criteria

Exclusion Criteria

  • Previous treatment with pegvaliase.
  • Use of any medication that is intended to treat PKU, including the use of large neutral amino acids, within 14 days prior to the administration of study drug on Day 1.
  • Use or planned use of any injectable drugs containing polyethylene glycol (PEG; other than pegvaliase), including medroxyprogesterone injection, within 3 months prior to the start of Screening/Run-in and during study participation with the exception of COVID-19 vaccinations.
  • A history of organ transplantation or on chronic therapy.
  • Use of any product or investigational medical device within 30 days prior to Screening/Run-in or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • A positive test for antibody, surface antigen, or antibody.
  • (ALT) concentration > 2 × the (ULN).
  • Creatinine > 1.5 × ULN.
  • Inability to identify and/or communicate to others that the participant is experiencing symptoms of potential anaphylaxis due to cognitive impairment or other reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Pegvaliase

    Treatment Arm

    Drug: Pegvaliase

  • Other
    Diet Only

    Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 215.

    Other: Diet Only

Interventions

  • Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week

    Also known as: PEG PAL, BMN 165

  • OtherDiet Only

    Diet Control

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.

    The blood Phe measurement following 72 weeks on study is defined as the average of the Week 69 and Week 73 blood Phe measurements. Change from baseline in blood Phe will be compared between participants in the active (pegvaliase) and the control (diet-only) treatment arms. Baseline blood Phe concentration at Part 1 was defined as the average of 3 pre-treatment measurements collected between Screening/Run-in (2) and Day 1 pre-dose (1).

    Time frame: Baseline to Week 72 (average of the Week 69 and Week 73)

  2. Incidence of Treatment-emergent Adverse Events (Part 1)

    Treatment-emergent adverse events (TEAE) is defined as any AE that newly appeared or worsened in severity after first dose of pegvaliase (pegvaliase arm) or on or after study day 1 (diet-only arm) until 30 days after last dose of the study. Serious adverse event (SAE).

    Time frame: Up to Week 73

  3. Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)

    The anti-pegvaliase total antibody (TAb) method captures drug-binding antibodies comprised of different isotypes and specificities. Antibody Positivity = number of subjects testing positive at any study visit / total number of subjects at study visit. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

  4. Percentage of Participants With Positive PAL IgG Antibody

    The presence of immunoglobulin G (IgG) Antibodies against phenylalanine ammonia lyase (PAL) is measured overtime. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

  5. Percentage of Participants With Positive PAL IgM Antibody

    The presence of immunoglobulin M (IgM) Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime. PAL IgM was positive if the titer value was greater than or equal to the median of all baseline PAL IgM titers. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

  6. Percentage of Participants With Positive PEG IgG Antibody

    The presence of IgG Antibodies against polyethylene glycol (PEG) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

  7. Percentage of Participants With Positive PEG IgM Antibody

    The presence of IgM Antibodies against PEG (polyethylene glycol) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

  8. Percentage of Participants With Positive Neutralizing Antibodies (NAb)

    Neutralizing antibodies (NAbs) capable of inhibiting the enzymatic activity of pegvaliase were measured. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

    Time frame: Baseline (Day 1), Week 73

Secondary outcomes

  1. Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study

    The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).

    Time frame: Baseline to Week 72 (average of Week 69 and week 73)

  2. Percentage Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study

    The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).

    Time frame: Baseline to Week 72 (average of Week 69 and week 73)

  3. Pegvaliase Tmax (Week 73 Intensive PK)

    Time to maximum observed plasma concentration (Tmax) for pegvaliase during the Week 73 intensive PK assessment, defined as the elapsed time from dosing to the sampling time at which the highest observed pegvaliase plasma concentration (Cmax) occurs based on the Week 73 plasma concentration-time profile. Pharmacokinetic (PK)

    Time frame: Week 73

  4. Pegvaliase Cmax (Week 73 Intensive PK)

    Maximum observed plasma concentration (Cmax) of pegvaliase during the Week 73 intensive PK assessment, defined as the highest measured pegvaliase plasma concentration across the Week 73 postdose sampling interval. Cmax is summarized in ng/mL concentration units based on observed values from the Week 73 concentration-time profile.

    Time frame: Week 73

  5. Pegvaliase AUC0-24 (Week 73 Intensive PK)

    Area under the plasma concentration-time curve from 0-24 hours postdose (AUC0-24) for pegvaliase during the Week 73 intensive PK assessment. AUC0-24 was calculated form the Week 73 plasma concentration-time data using noncompartmental methods and reported in ng\*h/mL units.

    Time frame: Week 73

  6. Pegvaliase Cavg (Week 73 Intensive PK)

    Average plasma concentration over the 0 to 24 hour postdose interval for pegvaliase during the Week 73 intensive PK assessment, reported in ng/mL concentration units, representing the mean pegvaliase exposure across the 24 hour postdose interval at Week 73.

    Time frame: Week 73

  7. Overall: Incidence of Treatment-emergent Adverse Events (Including Part 2)

    Time frame: Up to Week 153

  8. Part 2: Percentage of Participants With Anti-pegvaliase Total Antibody (TAb), Positive PAL IgG Antibody, Positive PAL IgM Antibody, Positive PEG IgG Antibody, Positive PEG IgM Antibody and Positive Neutralizing Antibodies (NAb)

    Time frame: Baseline (Day 1), Week 145

  9. Part 2: Pegvaliase Tmax, Cmax, AUC0-24 and Cavg (Week 145 Intensive PK)

    Time frame: Week 145

07

Results

Posted Jul 21, 2026

Participant flow

This study was conducted by 13 principal investigators at 13 study centers in the United States of America and 3 principal investigators at 3 study centers in Germany.

Part 1 (Through Week 72)
Participant flow — Part 1 (Through Week 72)
MilestoneExperimental: Pegvaliase (Part 1 and Part 2)Control: Diet Only (Part 1) Then Pegvaliase Treatment (Part 2)
Started3619
Completed3217
Not completed42
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject22
Part 2 (Week 73 Onwards)
Participant flow — Part 2 (Week 73 Onwards)
MilestoneExperimental: Pegvaliase (Part 1 and Part 2)Control: Diet Only (Part 1) Then Pegvaliase Treatment (Part 2)
Started3216
Completed part 1, did not enter part 2, continuing in study01
Completed00
Not completed3216
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Continuing in study3115

Outcome measures

PrimaryChange From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.

The blood Phe measurement following 72 weeks on study is defined as the average of the Week 69 and Week 73 blood Phe measurements. Change from baseline in blood Phe will be compared between participants in the active (pegvaliase) and the control (diet-only) treatment arms. Baseline blood Phe concentration at Part 1 was defined as the average of 3 pre-treatment measurements collected between Screening/Run-in (2) and Day 1 pre-dose (1).

Time frame:
Baseline to Week 72 (average of the Week 69 and Week 73)
Reported as:
Mean · µmol/L
Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.
µmol/LExperimental: PegvaliaseControl: Diet Only
Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.-449.9 ± 292.33-34.4 ± 272.07
Statistical analysis
  • Experimental: Pegvaliase vs Control: Diet Only · ANCOVA · p = <0.0001 (The imputation used the SAS procedure PROC MI; the variable list for imputation included baseline and post-baseline blood Phe measurements and stratified by treatment.)
PrimaryIncidence of Treatment-emergent Adverse Events (Part 1)

Treatment-emergent adverse events (TEAE) is defined as any AE that newly appeared or worsened in severity after first dose of pegvaliase (pegvaliase arm) or on or after study day 1 (diet-only arm) until 30 days after last dose of the study. Serious adverse event (SAE).

Time frame:
Up to Week 73
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (Part 1)
ParticipantsExperimental: PegvaliaseControl: Diet Only
Participants with Any AE3617
AEs assessed by investigator as related to study drug360
AEs leading to dose reduction90
AEs leading to dose interruption190
AEs leading to study drug discontinuation20
AEs leading to study discontinuation10
Participants with Any SAE21
SAEs assessed by investigator as related to study drug20
SAEs leading to dose reduction00
SAEs leading to dose interruption00
SAEs leading to study drug discontinuation20
SAEs leading to study discontinuation10
Participants who died00
PrimaryPercentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)

The anti-pegvaliase total antibody (TAb) method captures drug-binding antibodies comprised of different isotypes and specificities. Antibody Positivity = number of subjects testing positive at any study visit / total number of subjects at study visit. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)
percentage of participantsExperimental: Pegvaliase
Day 1100
Week 73100
PrimaryPercentage of Participants With Positive PAL IgG Antibody

The presence of immunoglobulin G (IgG) Antibodies against phenylalanine ammonia lyase (PAL) is measured overtime. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive PAL IgG Antibody
percentage of participantsExperimental: Pegvaliase
Day 122.2
Week 73100
PrimaryPercentage of Participants With Positive PAL IgM Antibody

The presence of immunoglobulin M (IgM) Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime. PAL IgM was positive if the titer value was greater than or equal to the median of all baseline PAL IgM titers. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive PAL IgM Antibody
percentage of participantsExperimental: Pegvaliase
Day 150.0
Week 7374.2
PrimaryPercentage of Participants With Positive PEG IgG Antibody

The presence of IgG Antibodies against polyethylene glycol (PEG) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive PEG IgG Antibody
percentage of participantsExperimental: Pegvaliase
Day 155.6
Week 733.2
PrimaryPercentage of Participants With Positive PEG IgM Antibody

The presence of IgM Antibodies against PEG (polyethylene glycol) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive PEG IgM Antibody
percentage of participantsExperimental: Pegvaliase
Day 1100
Week 73100
PrimaryPercentage of Participants With Positive Neutralizing Antibodies (NAb)

Neutralizing antibodies (NAbs) capable of inhibiting the enzymatic activity of pegvaliase were measured. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)

Time frame:
Baseline (Day 1), Week 73
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Neutralizing Antibodies (NAb)
percentage of participantsExperimental: Pegvaliase
Day 18.3
Week 7396.7
SecondaryChange From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study

The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).

Time frame:
Baseline to Week 72 (average of Week 69 and week 73)
Reported as:
Mean · g/kg
Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study
g/kgExperimental: PegvaliaseControl: Diet Only
Total Protein Intake0.00 ± 0.2670.01 ± 0.226
From Medical Food-0.20 ± 0.3410.03 ± 0.216
From Intact Food0.21 ± 0.369-0.02 ± 0.066
SecondaryPercentage Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study

The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).

Time frame:
Baseline to Week 72 (average of Week 69 and week 73)
Reported as:
Mean · percentage change
Percentage Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study
percentage changeExperimental: PegvaliaseControl: Diet Only
Total Protein Intake6.66 ± 32.24910.68 ± 43.144
From Medical Food-28.79 ± 42.49821.56 ± 73.388
From Intact Food106.66 ± 176.008-10.00 ± 22.828
SecondaryPegvaliase Tmax (Week 73 Intensive PK)

Time to maximum observed plasma concentration (Tmax) for pegvaliase during the Week 73 intensive PK assessment, defined as the elapsed time from dosing to the sampling time at which the highest observed pegvaliase plasma concentration (Cmax) occurs based on the Week 73 plasma concentration-time profile. Pharmacokinetic (PK)

Time frame:
Week 73
Reported as:
Mean · hrs
Pegvaliase Tmax (Week 73 Intensive PK)
hrsExperimental: Pegvaliase
Pegvaliase 20 mg12.0 ± NA
Pegvaliase 40 mg10.7 ± 5.08
Pegvaliase 60 mg8.66 ± 6.04
SecondaryPegvaliase Cmax (Week 73 Intensive PK)

Maximum observed plasma concentration (Cmax) of pegvaliase during the Week 73 intensive PK assessment, defined as the highest measured pegvaliase plasma concentration across the Week 73 postdose sampling interval. Cmax is summarized in ng/mL concentration units based on observed values from the Week 73 concentration-time profile.

Time frame:
Week 73
Reported as:
Mean · ng/mL
Pegvaliase Cmax (Week 73 Intensive PK)
ng/mLExperimental: Pegvaliase
Pegvaliase 20 mg2330 ± NA
Pegvaliase 40 mg2480 ± 3810
Pegvaliase 60 mg1750 ± 2200
SecondaryPegvaliase AUC0-24 (Week 73 Intensive PK)

Area under the plasma concentration-time curve from 0-24 hours postdose (AUC0-24) for pegvaliase during the Week 73 intensive PK assessment. AUC0-24 was calculated form the Week 73 plasma concentration-time data using noncompartmental methods and reported in ng\*h/mL units.

Time frame:
Week 73
Reported as:
Mean · h*ng/mL
Pegvaliase AUC0-24 (Week 73 Intensive PK)
h*ng/mLExperimental: Pegvaliase
Pegvaliase 20 mg46600 ± NA
Pegvaliase 40 mg17000 ± 27500
Pegvaliase 60 mg23200 ± 34000
SecondaryPegvaliase Cavg (Week 73 Intensive PK)

Average plasma concentration over the 0 to 24 hour postdose interval for pegvaliase during the Week 73 intensive PK assessment, reported in ng/mL concentration units, representing the mean pegvaliase exposure across the 24 hour postdose interval at Week 73.

Time frame:
Week 73
Reported as:
Mean · ng/mL
Pegvaliase Cavg (Week 73 Intensive PK)
ng/mLExperimental: Pegvaliase
Pegvaliase 20 mg1940 ± NA
Pegvaliase 40 mg2740 ± 4300
Pegvaliase 60 mg1550 ± 2070
SecondaryOverall: Incidence of Treatment-emergent Adverse Events (Including Part 2)
Time frame:
Up to Week 153

Results for this outcome have not been posted.

SecondaryPart 2: Percentage of Participants With Anti-pegvaliase Total Antibody (TAb), Positive PAL IgG Antibody, Positive PAL IgM Antibody, Positive PEG IgG Antibody, Positive PEG IgM Antibody and Positive Neutralizing Antibodies (NAb)
Time frame:
Baseline (Day 1), Week 145

Results for this outcome have not been posted.

SecondaryPart 2: Pegvaliase Tmax, Cmax, AUC0-24 and Cavg (Week 145 Intensive PK)
Time frame:
Week 145

Results for this outcome have not been posted.

Adverse events

Collected over Up to Week 73 (Part 1). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Pegvaliase0/36 (0%)2/36 (5.6%)36/36 (100%)
Control: Diet Only0/19 (0%)1/19 (5.3%)17/19 (89.5%)
Most frequent serious events
Most frequent serious events
EventExperimental: PegvaliaseControl: Diet Only
Anaphylactic reactionImmune system disorders2/360/19
HyperphenylalaninaemiaCongenital, familial and genetic disorders0/361/19
Most frequent other events
Showing 10 of 140
Most frequent other events
EventExperimental: PegvaliaseControl: Diet Only
Injection site erythemaGeneral disorders28/360/19
ArthralgiaMusculoskeletal and connective tissue disorders27/361/19
HeadacheNervous system disorders24/368/19
Injection site painGeneral disorders22/360/19
Injection site pruritusGeneral disorders19/360/19
Injection site swellingGeneral disorders17/360/19
PyrexiaGeneral disorders15/361/19
Upper respiratory tract infectionInfections and infestations15/367/19
CoughRespiratory, thoracic and mediastinal disorders8/367/19
Nasal congestionRespiratory, thoracic and mediastinal disorders9/367/19

Baseline characteristics

The Intent to Treat (ITT) population will consist of all participants who are randomized. Participants will be analyzed according to the randomized treatment for the analysis of efficacy.

Age, Continuous
Age, Continuous(years)Experimental: PegvaliaseControl: Diet OnlyTotal
Mean14.4 ± 1.2714.1 ± 1.2914.3 ± 1.27
Age, Customized
Age, Customized(Participants)Experimental: PegvaliaseControl: Diet OnlyTotal
12 years347
13 years505
14 years12719
15 years10616
16 years426
17 years202
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: PegvaliaseControl: Diet OnlyTotal
Female221133
Male14822
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: PegvaliaseControl: Diet OnlyTotal
Hispanic or Latino202
Not Hispanic or Latino341953
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: PegvaliaseControl: Diet OnlyTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American202
White301848
More than one race000
Unknown or Not Reported314
Region of Enrollment
Region of Enrollment(participants)Experimental: PegvaliaseControl: Diet OnlyTotal
United States281644
Germany8311
BMI
BMI(kg/m^2)Experimental: PegvaliaseControl: Diet OnlyTotal
Mean24.9 ± 5.4324.0 ± 6.3324.6 ± 5.71
Blood Phe Concentration
Blood Phe Concentration(µmol/L)Experimental: PegvaliaseControl: Diet OnlyTotal
Mean1025.3 ± 254.051028.6 ± 199.391026.4 ± 234.70

7 further baseline measures are reported on the registry.

08

Study locations

16 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jan 2025, 30 months.

Results were first posted in Jul 2026, 1 year 6 months after primary completion. A results delay was requested in Jul 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Mar 8, 2022
StartActual
Jun 17, 2022
Primary completionActual
Jan 14, 2025
CompletionEst.
Oct 2027
Results delay requested
Jul 22, 2025
Results first posted
Jul 21, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05270837
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
Jun 17, 2022
Primary completion
Jan 14, 2025
Completion
Oct 2027 (estimated)
Results posted
Jul 21, 2026
Last update
Jul 21, 2026

Study contacts

Study Director
study chair · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion